Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Gastrointestinal 8Other hematologic neoplasm 5Myeloid 3Lymphoid 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Congenital Bone Marrow Failure Syndromes 1

Interventions

Cyclophosphamide 11fludarabine phosphate 8fludarabine 8apixaban 8Mycophenolic Acid 6Melphalan 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rivaroxaban 4Filgrastim 4Biopsy 4thymoglobulin 3X-Rays 3Specimen Handling 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Enoxaparin 3Bone Marrow Transplantation 3Azacitidine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2olaparib 2Tretinoin 2Stem Cell Transplantation 2Mesna 2Injections 2Heparin, Low-Molecular-Weight 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Imatinib Mesylate × Classical hematology × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡